Phase 1 Study of ACR-2316 in Specific Advanced Solid Tumors
ConditionSpecific Advanced Solid Tumors
Trial statusRecruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age18+
SponsorAcrivon Therapeutics
About this trial
This is a first in-human, Open-label Phase 1 study to assess the safety of ACR-2316 for the treatment of subjects with specific, histologically confirmed, locally advanced, recurrent or metastatic solid tumors.
Eligibility criteria
Qualifiers
Signed written informed consent.
Histologically or cytologically proven metastatic, recurrent or locally advanced selected solid tumors.
Must be willing to provide redacted pathology report.
Subjects should have received no more than 3 lines of systemic therapy for recurrent disease.
Disqualifiers
Participants with known symptomatic brain metastases.
Participant had systemic therapy within 3 weeks prior to the first dose of study drug.
Participant had radiation therapy for curative intent within 4 weeks prior to the first dose of study drug.
Participant had palliative radiation therapy within 2 weeks prior to the first dose of study drug.
Trial design
Treatments tested in this trial
- ACR-2316
Treatment groups
100 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov